Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema. - Banerji A; Craig T; Sitz K; Li HH; Lumry W; Adatia A; Yang W; Jacobs JS; Tachdjian R; Soong W; Manning M; Wedner J; et al. (The Journal of allergy and clinical immunology, 2026)